Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. reports news as a medical technology company that develops and markets at-home therapies for chronic disorders. Its updates center on lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease, including products and platforms such as Flexitouch Plus, AffloVest airway clearance devices and LymphaTech's digital 3D measurement and monitoring technology.
Recurring company developments include quarterly financial results, clinical evidence for home-based therapies, FDA device clearances, product portfolio expansion, order-management and reimbursement workflow initiatives, acquisitions, share repurchase activity and board governance changes. The company's news also describes its work with clinicians to expand awareness and access to care for patients using at-home therapy systems.
Tactile Systems Technology (Nasdaq: TCMD) has announced its participation in the Canaccord Genuity 40th Annual Global Growth Conference on August 12th at 2:00 p.m. Eastern Time. The conference will be held virtually, and management will engage in a fireside chat. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for later replay. Tactile Medical focuses on at-home therapies for chronic diseases, notably with their pneumatic compression devices for conditions like lymphedema.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) reported a 22% decrease in second quarter revenue, totaling $35.1 million, down from $45.2 million in 2019, largely due to COVID-19 pandemic impacts. The operating loss surged to $8.0 million, contrasting with a $3.0 million profit in 2019. The company incurred a net loss of $13.9 million, or $(0.72) per diluted share. Despite challenges, management noted improvements in June compared to earlier months, and remains optimistic about recovery and growth in the $5 billion U.S. lymphedema market.
Tactile Medical (Nasdaq:TCMD) will release its second quarter fiscal 2020 financial results on August 3, after market close. The company's management will host a conference call at 5:00 p.m. ET to discuss the results, which can be accessed by dialing 877-407-3088 (international: 201-389-0927) with access code 13705943. A live webcast will also be available on Tactile Medical's investor relations website. The company specializes in developing devices for at-home treatment of chronic diseases, notably lymphedema and chronic venous insufficiency, aiming to improve patient care and reduce healthcare costs.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) announced the appointment of Daniel L. Reuvers as President and CEO, effective June 8, 2020, succeeding Gerald R. Mattys, who is retiring after 15 years of service. Reuvers, with over 30 years in the medical device industry, is expected to lead the company’s next growth phase. His previous role at Integra LifeSciences involved significant business leadership. Mattys will provide consulting until June 2021 for a smooth transition. The company focuses on at-home treatments for chronic diseases like lymphedema.
Summary not available.